Lilly receives $150 million for Cialis
This article was originally published in Scrip
Lilly will receive $150 million for licensing the commercialisation rights of Cialis (tadalafil) for pulmonary arterial hypertension to a biotechnology company, in which it is also buying a stake. United Therapeutics will pay the money up front to exclusively commercialise the phosphodiesterase V inhibitor for PAH in the US. Cialis, currently indicated for erectile dysfunction, is under regulatory review for the PAH indication in the US, Canada, Mexico, Japan and the EU. Pfizer already widely markets its similar erectile dysfunction drug Viagra (sildenafil) as Revatio for PAH. Lilly will manufacture and supply tadalafil to United Therapeutics and will retain global authority over the regulatory affairs, development, IP and manufacturing of tadalafil for all potential indications. It is buying $150 million of common United Therapeutics stock. The deal will strengthen United Therapeutics' strong portfolio of cardiovascular treatments. It already markets subcutaneous and intravenous Remodulin (treprostinil) for PAH. It has announced that the Freedom-C Phase III trial of oral trepsotinil missed its primary endpoint. Its share price fell to $58.62 at the end of trading, down from $90.52 on November 14th.